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A B S T R A C T
Background: Whilst injecting drugs in public places is considered a proxy for high risk behaviour among people
who inject drugs (PWID), studies quantifying its relationship with multiple drug-related harms are lacking and
none have examined this in the context of an ongoing HIV outbreak (located in Glasgow, Scotland). We aimed to:
1) estimate the prevalence of public injecting in Scotland and associated risk factors; and 2) estimate the as-
sociation between public injecting and HIV, current HCV, overdose, and skin and soft tissue infections (SSTI).
Methods: Cross-sectional, bio-behavioural survey (including dried blood spot testing to determine HIV and HCV
infection) of 1469 current PWID (injected in last 6 months) recruited by independent interviewers from 139
harm reduction services across Scotland during 2017–18. Primary outcomes were: injecting in a public place
(yes/no); HIV infection; current HCV infection; self-reported overdose in the last year (yes/no) and SSTI the last
year (yes/no). Multi-variable logistic regression was used to determine factors associated with public injecting
and to estimate the association between public injecting and drug-related harms (HIV, current HCV, overdose
and SSTI).
Results: Prevalence of public injecting was 16% overall in Scotland and 47% in Glasgow city centre. Factors
associated with increased odds of public injecting were: recruitment in Glasgow city centre (aOR=5.45, 95% CI
3.48–8.54, p<0.001), homelessness (aOR=3.68, 95% CI 2.61–5.19, p<0.001), high alcohol consumption
(aOR=2.42, 95% CI 1.69–3.44, p<0.001), high injection frequency (≥4 per day) (aOR=3.16, 95% CI
1.93–5.18, p<0.001) and cocaine injecting (aOR=1.46, 95% CI 1.00 to 2.13, p= 0.046). Odds were lower for
those receiving opiate substitution therapy (OST) (aOR=0.37, 95% CI 0.24 to 0.56, p<0.001) and older age
(per year increase) (aOR=0.97, 95% CI 0.95 to 0.99, p = 0.013). Public injecting was associated with an
increased risk of HIV infection (aOR=2.11, 95% CI 1.13–3.92, p = 0.019), current HCV infection (aOR=1.49,
95% CI 1.01–2.19, p= 0.043), overdose (aOR=1.59, 95% CI 1.27–2.01, p<0.001) and SSTI (aOR=1.42, 95%
CI 1.17–1.73, p<0.001).
Conclusions: These findings highlight the need to address the additional harms observed among people who
inject in public places and provide evidence to inform proposals in the UK and elsewhere to introduce facilities
that offer safer drug consumption environments.
Introduction
Globally, there are approximately 15.6 million people who inject
drugs (PWID) (Degenhardt et al., 2017) who are at risk of a range of
harms including blood-borne viruses (BBVs), skin and soft tissue in-
fections (SSTI) (Gordon & Lowy, 2005) and fatal and non-fatal overdose
(Degenhardt et al., 2011; Mathers et al., 2013). These harms are in-
fluenced by an individual's injecting environment (or their “risk
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environment”), which relates to physical, social, economic and political
factors at a macro- and micro-environmental level (Rhodes, 2002,
2009). An understanding of the current risk environments faced by
PWID is important to improve and tailor harm reduction services and
healthcare provision.
Public injecting (defined as the injection of drugs in an area ac-
cessible to the general public, such as alleyways, public toilets, stair-
wells, etc.) (Hunt, Lloyd, Kimber & Tompkins, 2007; Parkin &
Coomber, 2009; Tweed, Rodgers, Priyadarshi & Crighton, 2018) con-
cerns an individual's physical microenvironment (Rhodes et al., 2006).
Ethnographic research has demonstrated a number of features of these
environments that increase risk, such as lack of a hygienic area, in-
cluding access to clean water to wash hands and injecting sites, to fa-
cilitate good injecting hygiene. Additionally, poor lighting and hurried
injections increase the risk of missed hits (Small, Rhodes, Wood & Kerr,
2007). These environmental conditions increase the risk of abscesses,
SSTI, and other injection site-related issues (Salmon et al., 2009). Given
its public nature, PWID injecting in public places are also more likely to
experience arrest and incarceration (DeBeck et al., 2009; Hunter et al.,
2018; Ickowicz et al., 2017; Marshall, Kerr, Qi, Montaner & Wood,
2010; Small et al., 2007). Fear of assault and being discovered by the
public or the police encourages rushed higher risk injections where
PWID are less likely to follow safer injection practices
(Dovey, Fitzgerald & Choi, 2001; Small et al., 2007). These conditions
increase the risk of fatal and non-fatal overdose, which has been con-
sistently demonstrated in the literature (Darke, Kaye & Ross, 2001;
Hunter et al., 2018; Sutter, Curtis & Frost, 2019; Vallance et al., 2018;
Wallace, Kennedy, Kerr & Pauly, 2019).
PWID injecting in public places are often the most vulnerable and
marginalised members of society, with homelessness and socio-eco-
nomic deprivation being the strongest predictors of public injecting
(Havinga, Van der Velden, De Gee & Van der Poel, 2014; Hunt et al.,
2007; Ickowicz et al., 2017; Marshall et al., 2010; McKnight et al.,
2007; Navarro & Leonard, 2004; Vallance et al., 2018). Intertwined
with the precarious context associated with homelessness, public in-
jecting has also been associated with a higher severity of addiction with
complex health and social needs, which leads to higher intensity and
higher risk drug use (Navarro & Leonard, 2004; Vallance et al., 2018).
Furthermore, the social network dynamics of PWID who inject in public
places can normalise high risk injection behaviour (Tobin, Davey-
Rothwell & Latkin, 2010; Weeks et al., 2001); PWID injecting in public
are more likely to purchase, share (through the practices of “fron-
tloading” and “backloading”) and inject drugs in groups (Navarro &
Leonard, 2004). This increases the likelihood of sharing injecting
equipment, which has also consistently been associated with public
injecting (Hunter et al., 2018; Marshall et al., 2010; Mazhnaya, Tobin &
Owczarzak, 2018; McKnight et al., 2007; Navarro & Leonard, 2004;
Vallance et al., 2018; Wood et al., 2001).
While research has shown that public injecting is related to a
number of risk factors (such as the sharing of injecting equipment)
which increase the risk of BBV transmission, evidence on the direct
association between public injecting and serological evidence of BBV
infection is limited. Previous research has demonstrated a significant
association between public injecting and ever exposure (antibody po-
sitive) to hepatitis C virus (HCV) through serological testing
(Boodram, Golub & Ouellet, 2010; Maher, Chant, Jalaludin & Sargent,
2004). Only one previous study conducted during 1988–91 demon-
strated injecting in outdoor settings or abandoned buildings to be a
significant predictor of HIV seroconversion in low prevalence cities in
the United States (Friedman, Jose, Deren, Des Jarlais & Neaigus, 1995).
However, no study to our knowledge has demonstrated an association
between serological evidence of HIV and public injecting, in the era of
highly active anti-retroviral therapy (HAART), opioid substitution
therapy (OST) and needle and syringe provision. In addition, we are not
aware of any single study which considers the association between
multiple drug-related harms (including serological evidence of current
HCV/HIV, overdose and SSTI), and public injecting. The aims of this
study were thus to estimate: 1) the extent of public injecting in Scotland
and associated individual and demographic/environmental risk factors,
and 2) the association between public injecting and drug-related harms
(HIV, current HCV, overdose and SSTI). To the best of our knowledge,
this is the largest study and only one at a national level to have con-
sidered this. Further, our focus on public injecting is particularly war-
ranted in the context of the largest recorded outbreak of HIV among
PWID in the UK in the last 30 years, identified in Glasgow
(McAuley et al., 2019; Ragonnet-Cronin et al., 2018), in which public
injecting has been described as a prominent feature among cases
(Tweed et al., 2018).
Methods
Data source
This study utilised data collected in 2017–18 by the Needle
Exchange Surveillance Initiative (NESI), a national cross-sectional bio-
behavioural survey conducted every two years in Scotland since 2008
(Health Protection Scotland, 2019a). NESI aims to monitor the pre-
valence of BBVs and injecting risk behaviours among PWID. After
providing written informed consent, participants complete an inter-
viewer-led questionnaire and provide a dried blood spot (DBS) sample,
which is tested anonymously for BBV markers. Questions related to
public injecting were added to the most recent survey conducted be-
tween July 2017 and October 2018; the full questionnaire is available
at: https://www.hps.scot.nhs.uk/web-resources-container/needle-
exchange-surveillance-initiative-nesi-2008-09-to-2017-18/.
PWID were recruited by independent interviewers at 139 sites
providing harm reduction services across Scotland (approximately half
of the total nationally). Sites were chosen to be broadly representative
of the 11 regional administrative health areas (National Health Service
(NHS) Boards) in mainland Scotland. Inclusion criteria for participants
are: a) having injected drugs on at least one occasion (either recently
(last 6 months) or in the past) and b) no previous participation in the
current survey. We here considered current PWID, defined as those who
had injected in the previous six 6 months (relating to approximately
70% of the total sample). A total of 1469 PWID were available for
analysis, after the removal of: participants who had not injected in the
previous 6 months (n = 675) and duplicate participants (identified
using initials, gender and date of birth) (n = 61).
Outcomes
The primary outcomes of interest were: injecting in a public place in
the last 6 months (yes/no); HIV infection; current HCV infection;
overdose in the last year (yes/no) and SSTI the last year (yes/no). An
individual was considered to have injected in public if they had re-
ported injecting in a public toilet, car park, stairwell/close (communal
hall and stairway in residential building), outdoors (park, street, etc.)
and squat/abandoned house. Public injecting in the last 6 months was
used as both an outcome and exposure variable. HIV and HCV infection
were confirmed by laboratory DBS tests (Health Protection
Scotland, 2019a). HIV was detected using the Abbott Architect antigen/
antibody combination assay. HCV antibody was detected using the
Abbott Architect and HCV RNA was extracted and amplified using an
in-house real-time PCR method (Bennett et al., 2012). Samples which
tested both antibody and PCR positive were assumed to represent those
with current HCV infection.
We assessed outcomes according to relevant demographic/en-
vironmental and individual risk factors. Exposure variables refer to the
last 6 months unless stated otherwise. Demographic/environmental
exposures of interest included: gender (male/female), age, home-
lessness (yes/no), number of times in prison since first injected drugs
(≤5 times)/5> times), recruitment region (Glasgow city centre/
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Table 1
Demographics, risk behaviours, uptake of harm reduction services and harms reported by 1469 PWID in Scotland during 2017–18, according to their self report of
having injected in a public place in the previous 6 months.
Total samplea, N (%) PWID who reported public injectinga (% of
N)
χ2 P-valueb
Total (5 non-responses regarding public injecting) 1469 (100) 240 (16) N/A N/A
Demographics
Gender (4 non-responses)c
Male 1095 (75) 196 (18)
Female 366 (25) 43 (12) 7.6 0.006
Age (mean) 39.6 38.6 N/A N/A
Health board region
Glasgow city centre 219 (15) 102 (47)
NHS Greater Glasgow and Clyded 365 (25) 51 (14) 174.3 < 0.001
Rest of Scotland e 880 (60) 87 (10)
Homeless in the last 6 months (2 non-responses)
Yes 401 (27) 148 (37)
No 1061 (73) 91 (9) 170.8 < 0.001
Number of times in prison (13 non-responses)
5 or less 911 (63) 119 (13)
More than 5 542 (37) 119 (22) 19.6 < 0.001
Arrested for drug offenses in the last 6 months (39 non-responses)
Yes 182 (13) 38 (21)
No 1245 (87) 193 (16) 3.4 0.066
Risk behaviours
Injected heroin in the last 6 months (4 non-responses)
Yes 1345 (92) 221 (16)
No 118 (8) 19 (16) 0.1 0.926
Injected cocaine in the last 6 months (5 non-responses)
Yes 452 (31) 129 (28)
No 1010 (69) 111 (11) 70.1 < 0.001
Injected heroin and cocaine in the last 6 months (5 non-responses)
Yes 337 (23) 108 (32)
No 1125 (77) 132 (12) 78.0 < 0.001
Shared needles/syringes in last 6 months (14 non-responses)
Yes 141 (10) 34 (24)
No 1311 (90) 201 (15) 7.2 0.007
Years since first injection (16 non-responses)
<10 years 389 (27) 57 (15)
10+ years 1060 (73) 182 (17) 1.3 0.253
Average injection frequency in last 6 months (6 non-responses)
Low frequency (less than four times per day) 1345 (92) 186 (14)
High frequency (4 or more times per day) 117 (8) 54 (46) 81.9 < 0.001
Reused needle/syringe re-use in last 6 months (16 non-responses)
Yes 848 (58) 167 (20)
No 602 (42) 66 (11) 19.9 < 0.001
Unprotected sex in last 6 months
Yes 609 (42) 91 (15)
No 733 (50) 128 (17) 1.5 0.214
Unknown/missing 122 (8) 21 (17)
Alcohol consumption (>14 units per week) in the last 12 months (16 non-
responses)
Yes 317 (22) 100 (32)
No 1133 (78) 137 (12) 68.6 < 0.001
Coverage of harm reduction interventions
Received OST in the last 6 months (1 non-response)
Yes 1247 (85) 174 (14)
No 217 (15) 66 (30) 36.5 < 0.001
Needle/syringe coverage per injecting episode in last 6 months
100%+ 1016 (69) 149 (15)
< 100% 281 (19) 51 (18) 2.1 0.152
Unknown/missing 167 (11) 40 (24)
Naloxone prescribed in the last 12 months (18 non-responses)
Yes 1017 (70) 173 (17)
No 431 (30) 64 (15) 1.1 0.309
Harms
HIV infection
Yes 42 (3) 17 (40)
No 1332 (97) 210 (16) 17.6 < 0.001
Current HCV infection
Yes 402 (32) 99 (25)
No 840 (68) 111 (13) 25.2 < 0.001
Overdosed in the last year (32 non-responses)
Yes 264 (18) 78 (30)
No 1170 (82) 155 (13) 42.1 < 0.001
Skin and soft tissue infection in the last year (13 non-responses)
Yes 401 (28) 87 (22)
(continued on next page)
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Greater Glasgow and Clyde (excluding city centre)/rest of Scotland),
received opioid substitution therapy (OST) (yes/no), prescribed na-
loxone in the last 12 months (yes/no), arrested for drug offenses (yes/
no) and needle and syringe coverage per injecting episode (< 100%/
100%+). Individual risk factors of interest included: injected heroin
(yes/no), injected cocaine (yes/no), injected heroin and cocaine (yes/
no), injecting heroin and cocaine at the same time (also known as
‘snowballing’) (yes/no), shared needles/syringes (yes/no), years since
first injection (< 10 years/> 10+ years), injection frequency (≤4
times per day)/> 4 times per day), reused needle/syringe (yes/no),
unprotected sex (yes/no) and alcohol consumption (> 14 units per
week) (in line with UK Government guidance) in the last 12 months
(yes/no).
Analyses
The proportions of respondents having reported recent public in-
jecting were initially compared with those who had not across demo-
graphics, risk behaviours, uptake of harm reduction services and harm
variables using chi-squared tests of association. Unadjusted and ad-
justed logistic regression was subsequently used to estimate: 1) factors
associated with public injecting, 2) the association between public in-
jecting and HIV, current HCV, overdose and SSTI. Our modelling
methodology was underpinned by the minimum criteria for sample size
considerations in logistic regression, which states that there must be 10
events per independent variable included in the model
(Peduzzi, Concato, Kemper, Holford & Feinstein, 1996). Furthermore,
we used a significance level of p<0.05. To assess the potential of
multicollinearity in our models, we computed a correlation matrix to
ensure that none of the variables included were correlated with each
other. All correlation coefficients had an r-value of < ±0.50. Analysis
was undertaken using Stata 13.
Factors associated with public injecting
We grouped potential risk factors for public injecting into ‘in-
dividual’ and ‘demographic/environmental’ categories (as stated
above). The first model assessed demographic/environmental factors
associated with public injecting and the second model assessed in-
dividual factors associated with public injecting (can be viewed in
Appendix 1 and 2, respectively). Factors that were significant
(p<0.05) in both the individual and demographic/environmental
models were then entered into a combined model.
Harms (HIV, HCV, overdose and SSTI)
Four separate models were constructed, one for each drug-related
harm. All models were adjusted for age and gender. Co-variates in-
cluded in each model were based on known associations derived from
the literature and only included if the co-variate was associated with
both public injecting and the relevant harm. For the HIV model,
homelessness and cocaine injecting were included (McAuley et al.,
2019). The HCV model included homelessness, cocaine injecting, in-
jection frequency and alcohol consumption. The overdose model ad-
ditionally included homelessness, cocaine injecting, alcohol consump-
tion and injection frequency (O'Halloran et al., 2017; Riley et al., 2016).
The SSTI model included, homelessness, injecting heroin and cocaine at
the same time and injection frequency (Brown & Ebright, 2002). Full
models including co-variates can be viewed in the Appendix 3–6.
A multi-level framework was applied to each harms model to ac-
count for potential clustering across the 11 NHS Scotland board re-
cruitment regions. To account for clustering of HIV cases in NHS
Greater Glasgow and Clyde (NHS GGC) as a result of the ongoing HIV
outbreak (and too few observations elsewhere), the HIV multi-level
model framework was collapsed into NHS Greater Glasgow and Clyde
versus rest of Scotland.
Results
Participant characteristics
Of the 1469 PWID, the majority were male (75%, n= 1095) and the
mean age was 39.6 years (Table 1). Just over a quarter (27%, n= 401)
had experienced recent homelessness and 37% (n = 542) had been in
prison more than five times. The vast majority (92%, n = 1345) of the
sample had injected heroin in the past six months and 31% (n = 452)
reported injecting cocaine. The prevalence of HIV and current HCV
infection was 3% (n=42) and 32% (n= 402), respectively. Prevalence
of overdose and SSTI in the last year was 18% (n = 264) and 28%
(n = 401), respectively.
Prevalence of public injecting
Prevalence of public injecting among the overall sample was 16%
(n = 240), with highest rates in Glasgow city centre (47%, n = 102,
p<0.001) (Table 1). The prevalence of public injecting in other re-
cruitment areas and the injecting locations utilised can be viewed in the
Appendix 7 and 8. The prevalence of public injecting among those re-
porting homelessness, cocaine injecting and a high injection frequency
(> 4 times per day), was 37% (n = 148, p<0.001), 28% (n = 129,
p<0.001) and 46% (n = 54, p<0.001), respectively. There was a
lower prevalence among those reporting receiving OST (14%, n= 174,
p<0.001).
With regard to harms, the prevalence of public injecting among
those with HIV infection and active HCV infection was 40% (n = 17,
p<0.001) and 25% (n = 99, p<0.001), respectively. Among those
who reported overdose and SSTI, 30% (n = 78, p<0.001) and 22%
(n = 87, p<0.001) reported public injecting, respectively (Table 1).
Factors associated with public injecting
In our combined model (Table 2), public injecting was strongly
associated with recruitment region (p<0.001), with those recruited in
Glasgow city centre with nearly five and a half times the odds
(aOR=5.45, 95% CI 3.48 to 8.54) of reporting public injecting com-
pared to participants from the rest of Scotland. Public injecting was also
strongly associated with homelessness (aOR=3.68, 95% CI 2.61 to
5.19, p<0.001), alcohol consumption (> 14 units per week)
(aOR=2.42, 95% CI 1.69 to 3.44, p<0.001), high injection frequency
(≥4 times per day) (aOR=3.16, 95% CI 1.93 to 5.18, p<0.001) and
Table 1 (continued)
Total samplea, N (%) PWID who reported public injectinga (% of
N)
χ2 P-valueb
No 1052 (72) 150 (14) 11.8 0.001
a Total may not add up due to missing data.
b Missing values excluded from analysis.
c Non-responses/missing data is only presented if it is greater than 5% of the total sample.
d Excluding Glasgow city centre.
e Excluding NHS Greater Glasgow and Clyde.
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cocaine injecting (aOR=1.46, 95% CI 1.00 to 2.13, p= 0.046). Receipt
of OST (aOR=0.37, 95% CI 0.24 to 0.56, p<0.001) and older age (per
year increase) (aOR=0.97, 95% CI 0.95 to 0.99, p = 0.013) were as-
sociated with lower odds of public injecting.
Harms associated with public injecting
HIV infection
Prevalence of HIV infection among those who reported public in-
jecting was 7% (n= 17). PWID who reported public injecting had twice
the odds (aOR=2.11, 95% CI 1.13 to 3.92, p= 0.019) of being infected
with HIV (Table 3a).
Current HCV infection
Prevalence of current HCV infection was 47% (n = 99) among
PWID who reported public injecting. Those who reported public in-
jecting had one and a half times the odds of a current HCV infection
than PWID who did not (aOR=1.49, 95% CI, 1.01 to 2.19, p = 0.043)
(Table 3b).
Overdose
Prevalence of self-reported overdose in the last year was 33%
(n = 78) among PWID who reported public injecting. PWID who re-
ported public injecting had just over one and a half times the odds of
reporting an overdose in the last year (aOR=1.59, 95% CI, 1.27 to
2.01, p<0.001) (Table 3c).
Skin and soft tissue infection (SSTI)
Prevalence of self-reported SSTI infection in the last year was 37%
(n = 87) among PWID who reported public injecting. We found public
injecting was significantly associated with SSTI (aOR=1.42, 95% CI,
1.17 to 1.73, p<0.001) (Table 3d).
Discussion
In the context of one of the most persistent recent outbreaks of HIV
infection among PWID internationally (Des Jarlais et al., 2018) and the
largest the UK has seen in 30 years, we have examined the extent of
public injecting and associated harms in Scotland. We found that 16%
of PWID across Scotland, and 47% in Glasgow city centre, reported
public injecting. In multivariate analysis, the environmental factors
which were most strongly associated with an increased risk of public
injecting were recent experience of homelessness and study recruitment
in Glasgow city centre (i.e. the epicentre of the HIV outbreak). With
regard to individual risk factors, PWID reporting alcohol consumption
above recommended guidelines (> 14 units per week), a high injection
frequency (≥4 times per day) and cocaine injecting had a significantly
higher odds of reporting public injecting. We also found that public
injecting was strongly associated with HIV infection, current HCV in-
fection, and self-reported overdose and SSTI in the last year.
Our findings support the hypothesis that public injecting was a key
risk factor in the HIV outbreak in Glasgow (Tweed et al., 2018). As we
have measured the prevalence of HIV, rather than incidence, we cannot
deduce when individuals in the survey acquired their HIV infection.
However, it is likely that this occurred in the recent past (previous 3
years) in the context of the HIV outbreak and historical low prevalence
of HIV infection in previous NESI surveys (McAuley et al., 2019). Before
2017–18, the prevalence of HIV infection in this population was very
low; 1% during 2011–14 (1% in Glasgow city centre), rising to 2% in
2017–18 (11% in Glasgow city centre) (Health Protection
Scotland, 2019a; McAuley et al., 2019). Previous studies have found an
association between public injecting and risk behaviours (e.g. sharing
of injecting equipment) that can lead to HIV acquisition (Hunter et al.,
2018; Marshall et al., 2010; Mazhnaya et al., 2018; McKnight et al.,
2007; Navarro & Leonard, 2004; Vallance et al., 2018; Wood et al.,
2001). While the mechanism by which HIV transmission occurs is likely
due to the increased risk of sharing of injecting equipment as a result of
Table 2
Odds ratios (OR), adjusted odds ratios (aOR) and 95% confidence intervals (CI) of combined demographic/environmental and individual factors associated with
reporting public injecting in the last 6 months in Scotland, 2017–18.
Totala, N Reported public injecting in last 6 monthsb (% of N) Overall sample (n = 1464, 240 reported public injecting)
OR (95% CI) p-value aORe (95% CI) p-value
Age (per year increase) 39.5 38.6 0.98 (0.96 to 0.99) 0.030 0.97 (0.95 to 0.99) 0.013
Homeless in last 6 months
No 1061 91 (9) 1 < 0.001 1 <0.001
Yes 401 148 (37) 6.24 (4.64 to 8.38) 3.68 (2.61 to 5.19)
Number of times in prison since first injected drugs
Low number (5 incarcerations or less) 911 119 (13) 1 < 0.001 1 0.102
High number (more than 5 incarcerations) 542 119 (22) 1.87 (1.41 to 2.47) 1.33 (0.94 to 1.88)
Received OST in last 6 months
No 217 66 (30) 1 < 0.001 1 <0.001
Yes 1247 174 (14) 0.37 (0.27 to 0.51) 0.37 (0.24 to 0.56)
Injected cocaine in last 6 months
No 1010 111 (11) 1 < 0.001 1 0.046
Yes 452 129 (29) 3.23 (2.44 to 4.29) 1.46 (1.00 to 2.13)
Alcohol consumption (>14 units per week) in the last year
No 1133 137 (12) 1 < 0.001 1 <0.001
Yes 317 100 (32) 3.35 (2.49 to 4.51) 2.42 (1.69 to 3.44)
Average injection frequency in last 6 months
Low frequency (4 times per day or less) 1345 186 (14) 1 < 0.001 1 <0.001
High frequency (4 or more times per day) 117 54 (46) 5.34 (3.59 to 7.92) 3.16 (1.93 to 5.18)
Recruitment region
Rest of Scotlandc 880 87 (10) 1 1
NHS Greater Glasgow and Clyded 365 51 (14) 1.48 (1.02 to 2.14) 0.037 2.25 (1.46 to 3.47) < 0.001
Glasgow city centre 219 102 (47) 7.95 (5.62 to 11.22) < 0.001 5.45 (3.48 to 8.54) < 0.001
a Excludes missing data.
b May not add up to 240 PWID due to missing data.
c Excluding NHS Greater Glasgow and Clyde.
d Excluding Glasgow city centre.
e Adjusted for all co-variates presented in the table.
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the complex environmental conditions (Small et al., 2007), this is the
first time that the practice of public injecting has been found to be
associated with HIV infection based on serological evidence, in the
context of a comprehensive harm reduction environment
(McAuley et al., 2019). A previous small study conducted in 2001–2002
in Montreal which reported on serological evidence of HIV did not find
an association, likely due to a lack of power (Green, Hankins, Palmer,
Boivin & Platt, 2003). Furthermore, consistent with previous research
conducted in the USA pre HAART, we have demonstrated that public
injecting is an important risk factor in cities with a historically low
prevalence of HIV (Friedman et al., 1995). Our findings have illumi-
nated the potential role of public injecting, in addition to cocaine in-
jecting and homelessness (which were already considered important
drivers of HIV in Glasgow) (McAuley et al., 2019), in facilitating HIV
transmission amongst connected injection networks of PWID
(McAuley et al., 2019; Ragonnet-Cronin et al., 2018; Sypsa, 2019).
Despite a multi-pronged response, including expansion of HIV testing,
adoption of treatment as prevention approach through a nurse-led
outreach and community prescribing model and needle and syringe
provision (Metcalfe, Glover, Patton, Brown & Peters, 2018), this out-
break has persisted in contrast to other recent outbreaks of HIV
amongst PWID internationally (Des Jarlais et al., 2018), suggesting that
more needs to be done to address the wider determinants of HIV
transmission in this vulnerable population of PWID, such as public in-
jecting.
In addition to HIV infection, we also found an independent asso-
ciation between public injecting and current HCV infection. The pre-
valence of HCV among PWID is known to vary across Scotland, with
highest rates reported for Glasgow (Health Protection Scotland, 2019a).
Even considering those recruited from Glasgow city, the prevalence of
current HCV infection among PWID who reported public injecting
(47%) was higher than those who had not reported public injecting
(29%). The acquisition of HCV infection may have been acquired at any
time in the past, given the historically high prevalence of HCV in
Scotland (Health Protection Scotland, 2019a). Our results suggest that
PWID (infected with HCV) are engaging with high risk injection prac-
tices, which increases the risk of onward transmission and re-infection
among those treated. This is an important finding as could pose a threat
to efforts to eliminate HCV infection – both locally in Glasgow and
nationally in Scotland – in advance of the WHO 2030 global elimination
date (Health Protection Scotland, 2019b; World Health
Organisation, 2016).
Though the relationship between public injecting and overdose has
been well demonstrated, particularly in North America (Hunter et al.,
2018; Sutter et al., 2019; Vallance et al., 2018; Wallace et al., 2019), to
the best of our knowledge this is the first study which has demonstrated
an association between overdose and public injecting in the UK. This
has important implications and suggests that public injecting may be
contributing to Scotland's record levels of drug-related deaths (DRD)
(National Records of Scotland, 2019). Ethnographic research has de-
monstrated that the social context in which public injecting takes place
increases the risk of overdose due to PWID fear of arrest, assault or
discovery by the public. This unregulated environment causes rushed,
higher risk injections, in locations where PWID may not be discovered
immediately in the event of an overdose (Darke et al., 2001;
Small et al., 2007). The contexts of the high rates of DRD and overdose
between the UK and North America are distinct, with North America
experiencing a triple-wave epidemic driven initially by over-prescribing
prescription opioids, then by heroin, and subsequently by extremely
potent synthetic opioids such as fentanyl (Ciccarone, 2019). In contrast,
the situation in Scotland is different, with increasing DRD partly related
to an ageing population of PWID with complex health needs consuming
multiple drugs in combination, typically heroin, benzodiazepines and
alcohol (National Records of Scotland, 2019). However, what is high-
lighted in both settings is that the status quo harm reduction response is
no longer sufficient and new policies and interventions must be
Table 3
Odds ratios (OR), adjusted odds ratios (aOR) and 95% confidence intervals (CI) of harms (HIV, current HCV, overdose and SSTI) when reporting public injecting in
the last 6 months in Scotland, 2017–18.
a) HIV risk modelc, d Totala, N HIV infection (% of N)b HIV infection (n = 1375; 42 positive)
OR (95% CI) p-value aOR (95% CI) p-value
Reported public injecting
No 1135 25 (2) 1 < 0.001 1 0.019
Yes 227 17 (7) 3.59 (1.91 to 6.77) 2.11 (1.13 to 3.92)
b) Current HCV risk modelc, e Totala, N Current HCV infection (% of N)b Current HCV infection (n = 1376; 804 positive)
OR (95% CI) p-value aOR (95% CI) p-value
Reported public injecting
No 1032 303 (29) 1 < 0.001 1 0.043
Yes 210 99 (47) 2.14 (1.58 to 2.91) 1.49 (1.01 to 2.19)
c) Overdose risk modelc, f Totala, N Overdosed in last year (% of N)b Overdosed in last year (n = 1437; 265 overdose)
OR (95% CI) p-value aOR (95% CI) p-value
Reported public injecting
No 1201 186 (15) 1 < 0.001 1 <0.001
Yes 233 78 (33) 2.75 (2.01 to 3.76) 1.59 (1.27 to 2.01)
d) SSTI risk modelc, g Totala, N SSTI in the last year (% of N)b SSTI in last year (n = 1456; 402 SST)
OR (95% CI) p-value aOR (95% CI) p-value
Reported public injecting
No 1216 314 (26) 1 0.001 1 <0.001
Yes 237 87 (37) 1.67 (1.24 to 2.23) 1.42 (1.17 to 1.73)
a Excludes missing data.
b May not add up due to missing data.
c A multi-level framework was applied to each model to adjust for recruitment region, across the 11 NHS board areas. To account for clustering as a result of the
HIV outbreak in Glasgow, for the HIV model the multi-level framework was collapsed into NHS Greater Glasgow and Clyde vs. Rest of Scotland.
d Adjusted for age, sex, homelessness and cocaine injecting.
e Adjusted for age, sex, homelessness, cocaine injecting, injection frequency and alcohol consumption (> 14 units per week).
f Adjusted for age, sex, homelessness, cocaine injecting, injection frequency and alcohol consumption (> 14 units per week).
g Adjusted for age, sex, homelessness, injecting heroin and cocaine at the same time and injection frequency.
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considered to prevent these avoidable deaths.
Our findings are consistent with previous research demonstrating a
link between people who inject in public and SSTI (Salmon et al.,
2009), as a result of their highly unsanitary injecting environment
(Dunleavy, Hope, Roy & Taylor, 2019; Small et al., 2007) and the re-
duced likelihood of following injecting related hygiene practices
(Marshall et al., 2010). In recent years, Scotland has experienced major
outbreaks of spore-forming bacteria, including an outbreak of anthrax
(Palmateer, Ramsay, Browning, Goldberg & Hutchinson, 2012) and the
largest documented outbreak of wound botulism in Europe
(Trayner et al., 2018), both associated with a contaminated drug
supply. In both outbreaks, the majority of cases presented with SSTI
(Palmateer et al., 2012) and were engaged in high risk injection prac-
tices such as muscle/skin popping (a risk factor for SSTI) (Trayner et al.,
2018). Public injecting was not quantified in these previous outbreaks,
but the environmental conditions created by public injecting may have
been a contributing factor and certainly warrant further investigation.
Compared to “open drug scenes”, like the well-documented
Downtown Eastside in Vancouver (Small et al., 2007), public injecting
in the UK has been considered much less salient. However, in areas like
Glasgow, public injecting is often not visible to the general public,
despite being close to busy city centre restaurant and shopping areas
(Tweed et al., 2018). A needs assessment focusing on the health needs
of those injecting in public places in Glasgow was conducted in 2016
(Tweed et al., 2018), which estimated that there are 400–500 PWID
regularly injecting in public places in Glasgow city centre. The last
paper on public injecting in the UK was published in 2007 among a
small sample of PWID (n = 301) (Hunt et al., 2007), where they found
a public injecting prevalence of 55% among needle and syringe service
attendees in London and Leeds. While our national prevalence was
much lower (16%), rates in Glasgow city centre were comparable
(47%) and we found that those who were recruited in Glasgow city
centre had nearly a five and a half times higher odds of reporting public
injecting when compared to those recruited in the rest of Scotland. This
result in particular, should be of acute interest to policy makers in the
UK, given the recent rejection by the UK government to establish the
UK's first drug consumption room (DCR) in Glasgow city centre, which
has received considerable media attention (Atkinson, McAuley, Trayner
& Sumnall, 2019). We have provided substantial new evidence to in-
form the need for such an intervention, by demonstrating a high pre-
valence of public injecting and its association with drug-related harms.
This study adds to the large body of literature which demonstrates
how public injecting and the physical micro-environment in which in-
jecting drug use occurs predisposes individuals to harm (Hunter et al.,
2018; Rhodes, 2002, 2009; Small et al., 2007; Vallance et al., 2018).
DCRs provide an alternative, clean and safe environment for PWID
injecting in public; the evidence base in support of DCRs is substantial
(Pardo, Caulkins & Kilmer, 2018; Potier, Laprévote, Dubois-Arber,
Cottencin & Rolland, 2014), particularly in regard to reducing the
harms associated with public injecting (Potier et al., 2014; Wood et al.,
2004; Wood, Tyndall, Montaner & Kerr, 2006). Arguments for their
introduction, are particularly strong in areas such as Glasgow, which
are currently experiencing significant health crises among PWID
(Caulkins, Pardo & Kilmer, 2019; McAuley et al., 2019; Tweed et al.,
2018). Further weight could be added to the proposals in Glasgow by
assessing the acceptability of a DCR among vulnerable PWID in Scot-
land, which would provide an indication of both the demand for the
service and whether it would be successful at attracting high risk PWID.
However, given the multi-faceted nature of public injecting, the in-
troduction of DCRs should not be viewed as a panacea to address all
harms within this population. DCRs should be implemented as part of a
comprehensive harm reduction approach, including OST, needle ex-
change, safe injecting advice, naloxone and access to recovery services.
In areas of Scotland, there have been reports of sub-optimal me-
thadone dosing and of poor retention rates among PWID engaging with
OST services (House of Commons Scottish Affairs Committee, 2019),
despite approximately 70% of current PWID reported receiving OST in
the last 6 months (Health Protection Scotland, 2019a). We found that
OST was a protective factor against public injecting, which highlights
the importance and value of optimising, and where needed, extending
current drug treatment services. This includes, Heroin Assisted Treat-
ment (HAT), referring to the prescribing of injectable diamorphine as a
treatment for opiate dependence, which has just been made available in
Glasgow city centre embedded in a service providing care for those
experiencing homelessness. Furthermore, access to injecting equipment
provision services (that provide needles/syringes, foil, water, filters.
etc.) should also be enhanced, which has been a key response to the HIV
outbreak in Glasgow. Delivering harm reduction interventions through
outreach programmes, including peer and social network approaches to
the delivery of these services, could also further enhance their impact.
Furthermore, training and engagement with police on public health
approaches to issues with public drug use, has been shown to be ef-
fective in encouraging PWID to engage with harm reduction services
(Beletsky, Thomas, Shumskaya, Artamonova & Smelyanskaya, 2013;
DeBeck et al., 2008).
In addition to established harm reduction interventions, a number
of social and structural interventions should be considered to address
upstream social risk factors that lead PWID to public injecting, (such as
homelessness), including ensuring equitable access to housing and fi-
nancial benefits (Degenhardt et al., 2010). This should include in-
itiatives, such as Housing First, which consider “housing as harm re-
duction” to address the consistently overlapping issues of homelessness
and substance use (Pauly, Reist, Belle-Isle & Schactman, 2013). They do
not require individuals to undergo treatment for their substance use or
to be abstinent to access and keep permanent housing; by providing a
safe and secure environment they can reduce harms associated with
drug use and homelessness (Baxter, Tweed, Katikireddi & Thomson,
2019). A Housing First approach is a key component of the Glasgow
City Health and Social Care Partnership (HSCP) rapid rehousing tran-
sition plan, which aims to eliminate homelessness in Glasgow within 5
years (Glasgow City Health & Social Care Partnership, 2019). Further-
more, welfare and social security reform should also be considered,
including removing the sanctions based approach currently adopted by
the UK Government (House of Commons Scottish Affairs
Committee, 2019). This approach penalises individuals by reducing
welfare payments in response to failure to meet certain commitments
(such as failure to attend meetings), which disproportionately affect
individuals in precarious living situations (Economic & Social Research
Council, 2018). This is supported by a Canadian study, which showed
that receiving the most income from welfare was protective against
public injecting (Navarro & Leonard, 2004).
This study had a number of limitations which should be acknowl-
edged. Firstly, risk factor data and some outcome data (i.e. overdose
and SSTI) collected through NESI is self-reported, which may be subject
to response bias. However, this is considered minimal based on our use
of independent researchers to collect the data and previous research
(Darke, 1998). The sample is also biased towards those who utilised IEP
services, and thus may not fully represent the PWID population or
PWID who inject in public. However, data presented in the previously
described needs assessment (Tweed et al., 2018), highlighted that PWID
in Glasgow city centre (with nearly 50% injecting in public) are regular
attendees of needle and syringe provisions sites, which suggests that the
majority of PWID do attend these services. Although NESI collects data
on a wide range of risk factors, residual confounding may remain a
factor in our models. Furthermore, temporality cannot be established
with certainty in our analyses as some exposure data (such as home-
lessness and public injecting) refers to the last 6 months and some of
our outcomes (such as SSTI and overdose) refer to the last 12 months.
Additionally, recall bias may be present given participants were asked
to recall behaviours and harms from 6 months to a year.
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Conclusion
To the best of our knowledge, this is the first study to conduct a
national assessment of public injecting in the context of a large ongoing
HIV outbreak, where we have established, based on serological evi-
dence, that public injecting is independently associated with HIV in-
fection. We have also demonstrated that public injecting is associated
with multiple adverse outcomes, including current HCV, overdose and
SSTI, highlighting how the complex nature of the public injecting risk
environment increases risk of drug-related harm. Given the breadth of
these harms, these results highlight the need to address the issue of
public injecting, through a combination of interventions, including
those which consider how structural and social inequalities influence
the risk of harms. Furthermore, we have provided robust epidemiolo-
gical evidence to support the optimisation and expansion of harm re-
duction services internationally. Our findings specifically have re-
levance in the current context in the UK, by providing further weight to
proposals to establish the UK's first DCR in Glasgow and reinforce the
need for better harm reduction policies in the UK.
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